The brain is not static. It is continuously reshaping itself through a process called neuroplasticity — the ability to form new connections, strengthen existing pathways, and in some contexts, regenerate. Understanding how specific peptide compounds interact with the brain's signaling systems has become an increasingly active area of research, with implications for cognitive performance, stress resilience, neuroprotection, and the management of age-related cognitive decline.
The field of nootropic peptides sits at the intersection of neuroscience, endocrinology, and regenerative medicine. The research base is meaningful but not without important limitations — particularly regarding the volume of human clinical data for some compounds versus the depth of preclinical evidence. That distinction must be honored in any honest discussion of the topic.
BDNF: The Foundation of Neuroplasticity
Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family — a group of growth factors critical for the survival, development, and function of neurons. BDNF supports the growth of new synapses, promotes long-term potentiation (the cellular basis of learning and memory), and protects neurons against stress and injury.
Lower BDNF levels are consistently associated in the literature with depression, cognitive impairment, Alzheimer's disease risk, and reduced hippocampal volume. A 2014 meta-analysis in Neuropsychopharmacology (Molendijk et al.) documented significantly lower serum BDNF in individuals with major depressive disorder compared to controls, with levels rising following successful antidepressant treatment.
Physical exercise is the most robustly documented stimulus for BDNF upregulation. Aerobic exercise in particular — documented extensively in work by John Ratey at Harvard Medical School — reliably increases BDNF in the hippocampus, the brain region most critical to memory formation. Several of the peptide compounds discussed below appear to interact with BDNF signaling pathways.
Semax: ACTH-Derived Neuroprotection
Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — derived from the ACTH(4–7) fragment, a portion of adrenocorticotropic hormone. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has been approved in Russia and Ukraine as a nootropic and neuroprotective agent used clinically for stroke recovery, cognitive disorders, and optic nerve disease.
Mechanistically, Semax has been shown to upregulate BDNF and its receptor TrkB in animal and human studies. A 2008 study published in the Journal of Neurochemistry (Dolotov et al.) demonstrated that intranasal Semax administration significantly increased BDNF mRNA expression in the hippocampus and frontal cortex of rats. Semax also modulates the serotonin, dopamine, and enkephalin systems.
Small human studies conducted in Eastern Europe have reported improvements in attention, memory, and executive function, as well as neuroprotective effects following ischemic stroke. The compound is typically administered intranasally — unusual for a peptide — due to its ability to cross the nasal mucosa and reach the brain directly. Large Western randomized controlled trials do not yet exist for Semax, and it is not FDA-approved in the United States.
Selank: Anxiolytic Peptide Without Sedation
Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin — a tetrapeptide (Thr-Lys-Pro-Arg) with the addition of the sequence Pro-Gly-Pro. Also developed by the Institute of Molecular Genetics in Moscow, it has been registered as a medication in Russia for generalized anxiety disorder and neurasthenia.
Selank's most documented property is anxiolytic activity without the sedation, dependence risk, or cognitive blunting associated with benzodiazepines. A randomized clinical trial published in Bulletin of Experimental Biology and Medicine (Semenova et al., 2010) compared Selank to medazepam (a benzodiazepine) in patients with generalized anxiety disorder and found comparable anxiolytic effect with superior cognitive performance on Selank. Selank also appears to modulate IL-6, BDNF, and serotonin transporter activity.
Like Semax, Selank is typically administered intranasally, appears generally well-tolerated in available studies, and lacks large-scale Western clinical trials. Providers considering its use should weigh the meaningful but limited human evidence base and ensure informed consent regarding its investigational status in the U.S.
Dihexa: Synaptic Plasticity at the Research Frontier
Dihexa is a hexapeptide developed at Washington State University by Joseph Harding and colleagues, originally described in a 2013 publication in the Journal of Pharmacology and Experimental Therapeutics. It acts as a potentiator of hepatocyte growth factor (HGF) — a signaling molecule that promotes synaptogenesis (the formation of new synaptic connections) through binding to the Met receptor on neurons.
Dihexa is notable in the preclinical literature for its extraordinary potency relative to other cognitive-enhancing compounds. Animal studies demonstrated that it outperformed BDNF in improving cognitive performance in aged rats on memory tasks. However, the human evidence base is essentially non-existent — Dihexa has not been studied in clinical trials. It is a research compound in the strictest sense, and clinical use carries significant uncertainty. Providers evaluating it should approach it with appropriate caution and thorough informed consent.
The Clinical Framework for Cognitive Peptides
Cognitive performance is not isolated from systemic health. Before considering any peptide-based cognitive intervention, a CÉLURE provider evaluates the full physiological landscape: hormonal status (particularly testosterone and thyroid), metabolic biomarkers (fasting glucose, insulin, HbA1c), inflammatory markers (hsCRP, homocysteine), sleep quality, and cardiovascular health — all of which directly impact cognitive function independent of any peptide protocol.
Addressing systemic deficits first often yields the most meaningful cognitive improvement. Peptide protocols targeting neuroplasticity and neuroprotection are considered as adjuncts to — not replacements for — the foundational work of metabolic, hormonal, and lifestyle optimization.
Key References
- Dolotov OV, et al. Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Journal of Neurochemistry. 2006;99(2):518–528.
- Semenova TP, et al. Selective anxiolytic effect of Selank in a comparative study with diazepam and buspirone. Bulletin of Experimental Biology and Medicine. 2010;150(2):138–140.
- Benoist CC, et al. Facilitation of hippocampal synaptogenesis and spatial memory by a new peptide drug, dihexa. Journal of Pharmacology and Experimental Therapeutics. 2011;338(1):84–92.
- Molendijk ML, et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sun. PLOS ONE. 2012;7(11):e48046.
- Ratey JJ, Loehr JE. The positive impact of physical activity on cognition during adulthood: A review of underlying mechanisms, evidence, and recommendations. Reviews in the Neurosciences. 2011;22(2):171–185.
Educational Disclaimer: This article is for informational and educational purposes only. The compounds discussed are not FDA-approved for cognitive enhancement. This content does not constitute medical advice. Any clinical use requires evaluation and a valid prescription from a licensed provider.